1. Bluesky Feeds /
  2. Suleman Bhana, MD /
  3. Cardio-Rheumatology
Cardio-Rheumatology

Cardio-Rheumatology

by Suleman Bhana, MD Suleman Bhana, MD

This feed is to curate information on the emerging field of Cardiology-Rheumatology // Made at BlueskyFeeds.com

Feed on Bluesky

Feeds Stats

  • šŸ’™ Liked by 0 users
  • šŸ“… Updated about 1 year ago
  • āš™ļø Provider blueskyfeeds.com

Cardio-Rheumatology Likes over time

Like count prediction
The feed Cardio-Rheumatology has not gained any likes in the last month.

Feed Preview for Cardio-Rheumatology

Detroit Mash aka Heavy Pedal
@mubou-rider.bsky.social
about 2 hours ago
Gut health can accelerate your metabolism, increase your fiber and probiotic intake. Build up your natural glp1, greek yogurt, granola, fermented foods, protein, it can regulate your appetite while enhancing your metabolism.
1
0
1
Christina Stephens is exhausted.
@christinastephens.bsky.social
about 3 hours ago
The one that did me in was for a GLP1 medication that I couldnā€™t get approved by insurance, was too expensive for normal people to buy, was on shortage ā€¦ and it was a celebrity with the theme of ā€œWhy havenā€™t YOU taken control of diabetes yet!ā€ Uh ā€¦ what
0
0
2
@rxhometest.bsky.social
about 4 hours ago
This Heart Health Month, go beyond standard markers: -Lipoprotein(a): independent marker of heart health. Below 5 mg/dl-->ideal. Higher-->risk of inflammation & atherosclerosis -APOA1 (HDL related): higher->healthy -APOB (LDL related): lower->healthy -CRP: ideally <3 rxhometest.com/product/chol...
0
0
0
Betty C. Jung
@bettycjung.bsky.social
about 5 hours ago
However, population shifts in cardiometabolic risk phenotypes have resulted in similar or higher rates of obesity, diabetes, and hypertension in women than men. Additionally, the overall prevalence of smoking has decreased and is similar among men and women.
1
0
0
Offlately3.0
@offlately2.bsky.social
about 6 hours ago
My GLP1 arrives soon. So I have to go high protein/ fiber, low carb diet. I guess Iā€™ll see if I can even chock that down.
0
0
0
FlexNP
@rnflex.bsky.social
about 9 hours ago
When I write articles for my GLP1 blog I obsessively check my references over and over again for fear of this happening.
0
0
1
@gstpulldn.bsky.social
about 10 hours ago
People have tried with the coaching before at the gym, never drugs. Though I'm getting insulted by the targeted ads on YouTube. GLP1, ED drugs, hair loss drugs.
0
0
1
@burcon.bsky.social
about 10 hours ago
Excellent article on blending dairy and plant proteins! Explore how Burcon's #highpurity #plantproteins can complement your dairy formulations and enhance overall product performance www.foodingredientsfirst.ā€¦. #agtech #foodtech #innovation #plantbased #health #nutrition #esg #glp1
Bridging the gap: Will high-quality hybrids open the door to eating more protein?

www.foodingredientsfirst.com

Bridging the gap: Will high-quality hybrids open the door to eating more protein?

Food innovators are considering whether hybrid products &mdash; solutions made from both animal- and plant-based ingredients &mdash; could be an entry point into increased plant-based eating. Hybrids ...
1
0
0
@longevitytech.bsky.social
about 11 hours ago
Big pharma AstraZeneca partners with Hong Kongā€™s CSPC to develop next-gen weight management drugs worldwide. longevity.technology/newsā€¦. #longevity #metabolichealth #weightmanagement #biopharma #GLP1 #healthspan #pharmanews
0
0
0
DonPorque.com
@donporque.bsky.social
about 11 hours ago
ĀæPastillas para adelgazar? Novo y Lilly chocan con el precio #NovoNordisk #EliLilly #Wegovy #Ozempic #Zepbound #Obesidad #PastillasAdelgazar #Semaglutida #Tirzepatida #GLP1 #Farmaceuticas #Salud #3defebrero #felizmartes donporque.com/pastillas-pa...
ĀæPastillas para adelgazar? Novo y Lilly chocan con el precio

donporque.com

ĀæPastillas para adelgazar? Novo y Lilly chocan con el precio

Pastillas antiobesidad: Novo Nordisk y Eli Lilly aceleran la carrera, el precio se mueve y el mercado ajusta expectativas con datos, recetas. La guerra contra la obesidad acaba de entrar en esa fase e...
0
0
0
@the1andonlyjenn.bsky.social
about 12 hours ago
A GLP1 side effect that I never paid much attention to was Allodynia and I didnā€™t pay attention to it because after almost 2 years I had never experienced itā€¦ Until now! This is no joke! Has anyone else experienced this and if so, what do you do to soothe it?
Video thumbnail
Play button
0
0
0
ADA Professional Publications
@adapubs.bsky.social
about 12 hours ago
New journal for interdisciplinary care teams! Clinical guidance, obesity care, behavioral science & cardiometabolic insights in one resource. šŸŒŸ Online now | Print Feb 2026. šŸ‘‰ Explore & subscribe: diabetesjournals.org/docmā€¦
Cover of the January-February issue of Diabetes, Obesity, and Cardiometabolic Care journal, featuring a stylized illustration with various medical professionals and elements related to healthcare on a blue background, marked as new.
0
0
0
Wil Ranney
@wilranney.bsky.social
about 12 hours ago
I was thinking specifically with metformin. Iā€™m in the GLP1 trial.
0
0
1
OG
@oliviagoddess.bsky.social
about 13 hours ago
GLP1 are being investigated as a possible treatment. www.clickondetroit.com/neā€¦.
Researchers launch new study to test popular weight-loss drugs for long COVID treatment

www.clickondetroit.com

Researchers launch new study to test popular weight-loss drugs for long COVID treatment

Researchers are launching a new study to investigate whether GLP-1 drugs, already approved for type 2 diabetes and obesity, could help treat long COVID symptoms.
1
0
0
Chise
@sailorrooscout.bsky.social
about 13 hours ago
Overall mortality in unvaccinated individuals was roughly 50% HIGHER. The advantage held even after removing coronavirus-related deaths from the mix. The study has been published in JAMA. YES, it is PEER-REVIEWED. ā€¢ jamanetwork.com/journals/ā€¦. šŸ§ŖšŸ§µā¬‡ļø
Key Takeaways ā€¢ In a French cohort, the incidence of all-cause mortality among those who received a first dose of an mRNA COVID vaccine was 0.4% after a median follow-up of 45 months, compared with 0.6% of those who were unvaccinated. ā€¢After standardizing characteristics between the two groups, all-cause mortality incidence was 25% lower in those who had received a COVID shot. ā€¢ Vaccinated people were 74% less likely to die in a hospital because of COVID-19 compared with those who weren't vaccinated.
Key Points Question Are COVID-19 mRNA vaccines associated with the long-term risk of all-cause mortality? Findings In this cohort study including 22.7 million vaccinated individuals and 5.9 million unvaccinated individuals, vaccinated individuals had a 74% lower risk of death from severe COVID-19 and no increased risk of all-cause mortality over a median follow-up of 45 months. Meaning These national-level results found no increased risk of 4-year all-cause mortality in individuals aged 18 to 59 years vaccinated against COVID-19, further supporting the safety of the mRNA vaccines that are being widely used worldwide. Abstract Importance While several studies have assessed the impact of COVID-19 vaccination on short-term mortality, none have compared long-term mortality by vaccination status, particularly in young individuals who are less likely to experience severe disease following SARS- CoV-2 infection. Objective To compare 4-year all-cause mortality in individuals aged 18 to 59 years vaccinated with the mRNA COVID-19 vaccine vs unvaccinated individuals. Design, Setting, and Participants This cohort study used data from the French National Health Data System for all individuals in the French population aged 18 to 59 years who were alive on November 1, 2021. Data analysis was conducted from June 2024 to September 2025.
Exposure Exposure was defined as receiving a first mRNA dose between May 1 and October 31, 2021. Individuals who were unvaccinated by November 1, 2021, were assigned a random index date based on vaccinated individuals' vaccination dates. Main Outcomes and Measures Cox models weighted for sociodemographic characteristics and 41 comorbidities were used to estimate 4-year all-cause mortality. Time to event was censored at all-cause death, COVID-19 vaccination for unexposed individuals, or study termination on March 31, 2025. Complementary analyses were performed, including a comparison of the main causes of death available up to December 31, 2023. Follow-up began 6 months after the index date in both groups to address immortal time bias. Short-term mortality within 6 months after vaccination was assessed in a separate, independent study using adapted self-controlled case series models.
Results A total of 22767 546 vaccinated and 5932 443 unvaccinated individuals were followed up for a median (IQR) of 45(44-46) months. Vaccinated individuals were older than unvaccinated individuals (mean [SD] age, 38.0 [11.8] years vs 37.1 [11.4] years), more frequently women (11688 603 [51.3%] vs 2 876039 [48.5%]) and had more cardiometabolic comorbidities (2126 250 [9.3%] vs 464596 [7.8%]). During follow-up, 98 429 (0.4%) and 32 662 (0.6%) all-cause deaths occurred in the vaccinated and unvaccinated groups, respectively. Vaccinated individuals had a 74% lower risk of death from severe COVID-19 (weighted hazard ratio [wHR], 0.26 [95% CI, 0.22-0.30]) and a 25% lower risk of all-cause mortality (WHR, 0.75 [95% Cl, 0.75-0.761), with a similar association observed when excluding severe COVID-19 death. Sensitivity analysis revealed that vaccinated individuals consistently had a lower risk of death, regardless of the cause. Mortality was 29% lower within 6 months following COVID-19 vaccination (relative incidence, 0.71 [95% CI, 0.69-0.73]). Conclusions and Relevance In this national cohort study of 28 million individuals, the results found no increased risk of 4-year all-cause mortality in individuals aged 18 to 59 years vaccinated against COVID-19, further supporting the safety of the mRNA vaccines that are widely used worldwide.
4
57
164
Nature Metabolism
@natmetabolism.nature.com
about 14 hours ago
METABOLIC MESSENGERS | Testosterone S Bhasin, F Mauvais-Jarvis @harvardmed.bsky.social, @tulanemedicine.bsky.social Testosteroneā€™s role in cardiometabolic & musculoskeletal health šŸ§Ŗ
Metabolic Messengers: testosterone - Nature Metabolism

dlvr.it

Metabolic Messengers: testosterone - Nature Metabolism

Mauvais-Jarvis and Bhasin provide an in-depth review of testosteroneā€™s role in maintaining cardiometabolic health, musculoskeletal integrity and energy balance, drawing on evidence from testosterone replacement therapy in humans and mechanistic research in rodent models.
0
1
3
no_tag_error
@richardkeppler.bsky.social
about 14 hours ago
@negdiscountrt.bsky.social Based on experience, GLP1ā€™s are very helpful for controlling weight and diet and reducing compulsive behaviors of all kinds. The downsides are expense, a bit of digestive irregularities, and weight return when you get off it.
0
0
1
no_tag_error
@richardkeppler.bsky.social
about 14 hours ago
@negdiscountrt.bsky.social This isnā€™t my first go round with GLP1ā€™s, but it is cheaper, is overseen by physicians and blood tests, and includes a very helpful app that tracks all my daily stats, particularly food.
0
0
2
NDR, Jones' Act Disrespecter
@negdiscountrt.bsky.social
about 14 hours ago
I thought you were perhaps exaggerating but you are exactly right. The company is based on selling GLP1 drugs. www.emed.com/join/home

www.emed.com
2
0
0
Anadarko
@anadarkocapital.bsky.social
about 14 hours ago
Yaccarino is peddling GLP1s at a TeleHealth company, which makes sense. Very bad actors in the GLP1 telehealth space.
0
0
2
medRxivpreprint
@medrxivpreprint.bsky.social
about 15 hours ago
Abdominal subcutaneous fat is a stronger predictor of cardiometabolic risk markers than visceral fat in young lean rural Indians www.medrxiv.org/content/1ā€¦
0
0
0
thatstanishk.bsky.social
@thatstanishk.bsky.social
about 16 hours ago
JUST IN: ADM CEO JUAN LUCIANO SAYS STARCHES & SWEETENERS DEMAND HURT BY GLP1 DRUGS USE, ELEVATED PRICES & MOVES AWAY FROM ULTRA-PROCESSED FOODS, AS PER REUTERS X
0
0
0